Liver transplantation for hepatitis B virus: Decreasing indication and changing trends

Table 1 Characteristics of the study population, both overall and grouped by recurrence n (%)

Characteristics
Age (yr)	50.6 ± 11.0	44.3 ± 16.2	51.4 ± 9.9	0.022
Gender
Male	106 (80)	14 (13)	92 (87)	0.16
Female	27 (20)	1 (3.7)	26 (96)
Posttransplantation follow-up (mo)	82 (1-274)1	206 (74-274)	53 (1-254)	< 0.0001
Pretransplantation HBsAg
Negative	6 (5)	0	6 (5)	0.37
Positive	126 (95)	15 (100)	111 (95)
Pretransplantation HBeAg
Negative	108 (81)	6 (40)	102 (87)	< 0.00012
Positive	24 (19)	9 (60)	15 (134)
Pretransplant HBV DNA
Negative	86 (73)	4 (60)	82 (73)	0.03
Positive	36 (27)	6 (60)	30 (26)
HBIG duration (mo)1	14 (1-140)	14 (1-140)	14 (1-132)	0.83
MELD score	20.8 ± 7.6	19.2 ± 7.7	21.0 ± 7.6	0.39
Posttransplantation HBsAg
Negative	114 (88)	3 (20)	111 (97)	< 0.00012
Positive	16 (12)	12 (80)	4 (3)
Posttransplant HBeAg
Negative	122 (96)	11 (73)	111 (99)	< 0.00012
Positive	5 (4)	4 (5)	1 (1)
HDV coinfection
Negative	70 (69)	8 (80)	62 (67)	0.41
Positive	32 (31)	2 (20)	30 (33)

¹The results are expressed as the median (range);

²Significant at P < 0.05. HDV: Hepatitis delta virus; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus.